Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLKNASDAQ:APLMNASDAQ:BCABNASDAQ:DYAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.20 million shsN/AAPLMApollomics$6.44-6.9%$6.12$4.47▼$35.98$7.10M0.999,567 shs3,936 shsBCABBioAtla$0.41-5.3%$0.41$0.24▼$2.53$23.69M0.92938,824 shs196,590 shsDYAIDyadic International$0.94-0.4%$1.10$0.93▼$2.24$28.29M0.9255,515 shs36,110 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+33.24%-74.29%APLMApollomics-6.94%-1.90%+23.61%-14.20%-70.86%BCABBioAtla-5.32%-15.85%-0.98%+17.95%-74.34%DYAIDyadic International-0.44%-5.05%-9.62%-31.88%-54.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos3.8805 of 5 stars3.15.00.04.70.02.51.3APLMApollomics1.2433 of 5 stars0.05.00.00.03.30.00.6BCABBioAtla2.8039 of 5 stars3.32.00.00.02.72.51.3DYAIDyadic International2.1937 of 5 stars3.52.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.20Hold$2.00507.72% UpsideAPLMApollomics 0.00N/AN/AN/ABCABBioAtla 2.50Moderate Buy$5.001,133.05% UpsideDYAIDyadic International 3.00Buy$6.00538.30% UpsideCurrent Analyst Ratings BreakdownLatest APLM, ALLK, BCAB, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025BCABBioAtlaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AAPLMApollomics$1.22M5.82N/AN/A$47.51 per share0.14BCABBioAtla$11M2.15N/AN/A$1.47 per share0.28DYAIDyadic International$3.34M8.46N/AN/A$0.20 per share4.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)APLMApollomics-$172.60MN/A0.00∞N/AN/AN/AN/AN/ABCABBioAtla-$123.46M-$1.22N/AN/AN/AN/A-187.30%-96.33%8/6/2025 (Estimated)DYAIDyadic International-$6.80M-$0.20N/AN/AN/A-188.09%-149.16%-59.81%8/12/2025 (Estimated)Latest APLM, ALLK, BCAB, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 million5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/A3/27/2025Q4 2024BCABBioAtla-$0.40-$0.32+$0.08-$0.34N/AN/A3/26/2025Q4 2024DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$1.60 million$0.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/AAPLMApollomicsN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08APLMApollomicsN/A2.25N/ABCABBioAtlaN/A3.113.11DYAIDyadic International1.545.155.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%APLMApollomics19.13%BCABBioAtla77.23%DYAIDyadic International27.95%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%APLMApollomicsN/ABCABBioAtla11.50%DYAIDyadic International29.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableAPLMApollomics451.10 millionN/ANot OptionableBCABBioAtla6058.42 million42.79 millionOptionableDYAIDyadic International730.09 million21.07 millionOptionableAPLM, ALLK, BCAB, and DYAI HeadlinesRecent News About These CompaniesDyadic International, Inc. Announces Leadership Change and Strategic Shift Towards Ancillary Protein MarketJune 2, 2025 | quiverquant.comDyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial ApplicationsJune 2, 2025 | globenewswire.comEarnings call transcript: Dyadic Q1 2025 revenue misses, stock rises 3.85%May 16, 2025 | investing.comDYAI: Fermbox Purchase OrderMay 16, 2025 | msn.comDyadic International, Inc. (DYAI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comDyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company ProgressMay 14, 2025 | finance.yahoo.comDyadic International, Inc. to Announce First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025May 1, 2025 | quiverquant.comDyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025May 1, 2025 | globenewswire.comDyadic International, Inc. CEO to Present at 2025 World Vaccine Congress on Advancements in Biomanufacturing for VaccinesApril 16, 2025 | quiverquant.comDyadic to Present at World Vaccine Congress | WashingtonApril 16, 2025 | globenewswire.comHow to complete the Dyadic Perfection quest in Destiny 2April 3, 2025 | siege.ggEarnings call transcript: Dyadic Q4 2024 shows revenue beat, EPS missMarch 28, 2025 | investing.comDyadic International, Inc. (NASDAQ:DYAI) Q4 2024 Earnings Call TranscriptMarch 28, 2025 | msn.comDYAI: CEPI Grants Recognize C1March 28, 2025 | msn.comQ4 2024 Dyadic International Inc Earnings CallMarch 27, 2025 | uk.finance.yahoo.comDyadic International, Inc.: Dyadic Reports 2024 Year-End Financial Results and Business UpdatesMarch 27, 2025 | finanznachrichten.deDyadic International files to sell 840K shares of common stock for holdersMarch 27, 2025 | markets.businessinsider.comDyadic International, Inc. (DYAI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comDyadic Reports 2024 Year-End Financial Results and Business UpdatesMarch 26, 2025 | globenewswire.comDyadic International receives a funding award from CEPIMarch 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLM, ALLK, BCAB, and DYAI Company DescriptionsAllakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Apollomics NASDAQ:APLM$6.44 -0.48 (-6.94%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$6.50 +0.06 (+0.92%) As of 06/13/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.BioAtla NASDAQ:BCAB$0.41 -0.02 (-5.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.44 +0.03 (+8.26%) As of 06/13/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Dyadic International NASDAQ:DYAI$0.94 -0.01 (-0.55%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
